The potential impact of azithromycin in idiopathic pulmonary fibrosis

Eur Respir J. 2019 Feb 14;53(2):1800628. doi: 10.1183/13993003.00628-2018. Print 2019 Feb.

Authors

Claudio Macaluso^{1

2}, Joaquín Maritano Furcada^{1

2}, Omamah Alzaher¹, Ritesh Chaube¹, Felix Chua¹, Athol U Wells¹, Toby M Maher^{1

3}, Peter M George¹, Elizabeth A Renzoni¹, Philip L Molyneaux^{1

3}

Affiliations

¹ Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
² These authors contributed equally to the study.
³ Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK.

PMID: 30442715
DOI: 10.1183/13993003.00628-2018

No abstract available

Publication types

Letter
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Anti-Bacterial Agents / therapeutic use
Azithromycin / therapeutic use*
Disease Progression
Female
Hospitalization
Humans
Idiopathic Pulmonary Fibrosis / drug therapy*
Immunosuppressive Agents / therapeutic use
Macrolides / therapeutic use*
Male
Middle Aged
Retrospective Studies
Vital Capacity

Substances

Anti-Bacterial Agents
Immunosuppressive Agents
Macrolides
Azithromycin

Grants and funding